upcoming investor conferences
Marseille, France, December 12, 2017, 7:00 AM CET
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present at the following investor events during the first quarter of 2018:
- J.P. Morgan Annual Healthcare Conference - San Francisco, January 8-10, 2018
- Oddo BHF Forum - Lyon, January 11-12, 2018
- Innate Pharma R&D Day - London, March 8, 2018
*****
The Company will host an
R&D Day on March 8th, 2018,
in London, UK, from 1:00 to 5:00 pm GMT.
Innate Pharma`s management team will highlight Innate`s leading scientific role in immuno-oncology and its emerging proprietary portfolio, provide a more in-depth look at lead projects, IPH4102 and IPH5401, and their commercial potential.
The event is intended for institutional investors and sell-side analysts only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a spot, please contact Consilium Strategic Communications, at InnatePharma@consilium-comms.com.
*****
Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company`s website in the Investors` section (http://www.innate-pharma.com/en/investors ).
About Innate Pharma:
Innate Pharma S.A. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immunity.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body`s immune system to recognize and kill cancer cells.
The Company`s broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs.
Innate Pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of Natural Killer cell biology. This innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi. Innate Pharma is building the foundations to become a fully-integrated biopharmaceutical company.
Based in Marseille, France, Innate Pharma has more than 180 employees and is listed on Euronext Paris.
Learn more about Innate Pharma at www.innate-pharma.com